Friends, This message was received on Twitter from Prof. Diwan S Rawat: "Finally after 10 years of sustained hard work our work on Parkinson got accepted by Nature Communication. The molecule has been taken up by Boston based Pharma industry to develop as a drug for the treatment of Parkinson disease! This is the hybrid molecule consisting aminoquinoline and pyrimidine pharmacophore. Prof Kim from McLean Hospital Boston is our collaborator. This molecule activate Nurr1 receptor that stops death of dopamin neuron, it also stops aggregation of alpha synuclien." We have to wait till the paper appears in Nature Communication to know the details! The authors have to pay more than $10,000 to Springer-Nature as publication charges. They could have made it available to everyone by placing the paper in medRxiv at no cost! Most likely the research was carried out with public funding/taxpayers' money. Arun -- This message has been scanned for viruses and dangerous content by MailScanner, and is believed to be clean.